Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor

被引:38
作者
Kamiyama, H [1 ]
Zhou, G [1 ]
Roizman, B [1 ]
机构
[1] Univ Chicago, Marjorie B Kovler Viral Oncol Labs, Chicago, IL 60637 USA
关键词
HSV-1; recombinant; malignant glioma; uPAR; GPI-anchor;
D O I
10.1038/sj.gt.3302685
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Earlier this laboratory constructed a herpes simplex virus 1 recombinant (R5111) that carries a IL13 ligand inserted into glycoprotein D and can enter cells via the IL13R alpha 2 receptor commonly expressed on the surface of malignant glioma cells. In this report, we describe the properties of two recombinant viruses carrying chiemric gD genes. In R5181 recombinant virus the chimeric gene consisted on the residues 20 - 155 of urokinase plaminogen activator (uPA) inserted between residues 24 and 25 of gD. In R5182 the insert consisted of a 23-residue sequence encoding the uPA binding domain for the urokinase plaminogen activator receptor ( uPAR). These viruses were constructed for three reasons, to increase the number of viruses that specifically target receptors on the surface of malignant glioma cells, to determine whether viruses exhibiting novel ligands could enter cells via receptors anchored to the cell surface via glycosylphosphatidylinositol anchor as has been recently demonstrated for nectin1, and to determine whether receptors other than IL13R alpha 2 could be targeted by genetic engineering of the virus. We report that R5181 but not R5182 recombinant virus was able to enter cells expressing uPAR. The results indicate that HSV-1 recombinant viruses can be engineered to enter cells via a variety of unrelated nonviral receptors, including receptors that are anchored to the cells surface but without transmembrane domains.
引用
收藏
页码:621 / 629
页数:9
相关论文
共 21 条
[1]  
BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865
[2]   Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma [J].
Cantero, D ;
Friess, H ;
Deflorin, J ;
Zimmermann, A ;
Brundler, MA ;
Riesle, E ;
Korc, M ;
Buchler, MW .
BRITISH JOURNAL OF CANCER, 1997, 75 (03) :388-395
[3]   THE STRUCTURE AND BIOSYNTHESIS OF GLYCOSYL PHOSPHATIDYLINOSITOL PROTEIN ANCHORS [J].
ENGLUND, PT .
ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 :121-138
[4]   Binding of human single chain urokinase to Chinese hamster ovary cells and cloning of hamster u-PAR [J].
Fowler, B ;
Mackman, N ;
Parmer, RJ ;
Miles, LA .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (01) :148-154
[5]   Entry of herpes simplex virus mediated by chimeric forms of nectinl retargeted to endosomes or to lipid rafts occurs through acidic endosomes [J].
Gianni, T ;
Campadelli-Fiume, G ;
Menotti, L .
JOURNAL OF VIROLOGY, 2004, 78 (22) :12268-12276
[6]  
GLADSON CL, 1995, AM J PATHOL, V146, P1150
[7]   Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread [J].
Laquerre, S ;
Argnani, R ;
Anderson, DB ;
Zucchini, S ;
Manservigi, R ;
Glorioso, JC .
JOURNAL OF VIROLOGY, 1998, 72 (07) :6119-6130
[8]   Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial [J].
Markert, JM ;
Medlock, MD ;
Rabkin, SD ;
Gillespie, GY ;
Todo, T ;
Hunter, WD ;
Palmer, CA ;
Feigenbaum, F ;
Tornatore, C ;
Tufaro, F ;
Martuza, RL .
GENE THERAPY, 2000, 7 (10) :867-874
[9]  
MOLLER JV, 1993, J BIOL CHEM, V268, P18659
[10]  
NELLES L, 1987, J BIOL CHEM, V262, P5682